
Turner MedTech Joins the Prestigious Inc. 5000 List
August 15, 2024
Orem, Utah – August 13, 2024 Turner MedTech, a leading innovator in the medical device and biotechnology sector, is proud to announce its inclusion in the esteemed Inc. 5000 list, a hallmark of entrepreneurial success. The Inc. 5000 list represents a unique look at the most successful companies within the American economy’s most dynamic segment—its independent small businesses.
Turner MedTech’s recognition on the Inc. 5000 list heralds the company’s growth and industry impact, offering a vibrant, opportunity-rich work environment. This distinction also bolsters the company’s standing, attracting leading professionals and fostering a culture of innovation and development.
“Being recognized on the Inc. 5000 list is a testament to the hard work and dedication of our team,” said Dr. D. Clark Turner, President & CEO of Turner MedTech. “Our commitment to innovation and excellence in the medical and life sciences industries has driven our growth and success.”
Turner MedTech, headquartered at 1119 South 1680 West, Orem, UT, has been at the forefront of medical and technological advancements, focusing on the manufacture of products for a variety of industries, including medical, life science, physical science, and security and defense. With a seamless quality system and a dynamic approach to product development, Turner MedTech has accelerated the commercialization timeline for its customers, contributing significantly to the field.
The Inc. 5000 inclusion highlights Turner MedTech’s consistent revenue growth and its position as a leader in the industry. This achievement reflects the company’s ongoing innovation and its ability to meet the evolving needs of its customers.
For more information about Turner MedTech and its services, please visit www.turnermedtech.com or contact the company at (801) 796-2951.
Recent News
- BioUtah’s 2026 Utah Life Sciences Summit Recap
- 2026 Life Sciences Awards to be Presented at the Mayer Brown Utah Life Sciences Summit
- PROGRESS TRIAL DEMONSTRATES EDWARDS TAVR IS SUPERIOR TO CLINICAL SURVEILLANCE FOR MODERATE AS PATIENTS WITH AT-RISK FEATURES
- Denali Therapeutics Receives 2026 Prix Galien USA Award for AVLAYAH® (tividenofusp alfa-eknm) as Best Biotechnology Product
- Utah Business, Government Leaders Deepen Connections in Ireland
- Co-Diagnostics’ Joint Venture CoSara Diagnostics Announces Publication of Peer-Reviewed HPV Screening Study Using CoSara’s SARAGENE® Test














